Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.97 |
| ▸ | EGFR | P00533 | 8/20 | 0.60 |
| ▸ | KDR | P35968 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | GOT1 | P17174 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MPO | P05164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Todralazine SCHEMBL29673003 | 1.00 | LMNA (1.00) | LMNACYP1A2CYP2D6HIF1ATDP1 | |
| Todralazine SCHEMBL211261 | 0.99 | TDP1 (1.00) | LMNACYP1A2CYP2D6HIF1ATDP1 | |
| Todralazine SCHEMBL1417412 | 0.97 | TDP1 (0.97) | LMNACYP1A2CYP2D6HIF1ATDP1 | |
| SCHEMBL31506911 | 0.80 | LMNA (0.67) | LMNACYP1A2CYP2D6HIF1ATDP1 | |
| SCHEMBL12106741 | 0.77 | LMNA (0.62) | LMNACYP1A2CYP2D6HIF1ATDP1 | |
| SCHEMBL14543960 | 0.77 | EGFR (0.63) | LMNACYP1A2CYP2D6HIF1ATDP1 | |
| SCHEMBL12765309 | 0.77 | LMNA (0.61) | LMNACYP1A2CYP2D6HIF1ATDP1 | |
| SCHEMBL28900093 | 0.74 | NPC1 (0.71) | LMNACYP1A2CYP2D6HIF1ATDP1 | |
| SCHEMBL8842155 | 0.74 | CYP1A2 (0.58) | LMNACYP1A2CYP2D6HIF1ATDP1 | |
| SCHEMBL18607384 | 0.74 | LMNA (0.58) | LMNACYP1A2CYP2D6HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1561 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118252921-A | Use of GIP receptor agonists | 杭州中美华东制药有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118240917-A | Method for detecting biological activity of GLP-1, GLP-1 analogue or GLP-1 fusion protein | 正大天晴药业集团南京顺欣制药有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-117398471-A | Polypeptide composition, medicine, pharmaceutical composition and application thereof | 合肥天汇生物科技有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-109803639-B | New formulation | 艾瑞克有限公司 | 2024-01-02 | — | — | CN | claimed |
| WO-2023230770-A1 | METHODS OF LUNG ADENOCARCINOMA TREATMENT WITH NON ANTI-LUAD DRUGS OR COMPOUNDS | Suzhou Singleron Biotechnologies Co., Ltd. (CN) | 2023-12-07 | — | — | WO | claimed |
| CN-116745289-A | Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor | 奥洛治疗有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-116615430-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-08-18 | — | — | CN | claimed |
| CN-116547279-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-08-04 | — | — | CN | claimed |
| CN-109715662-B | Methods of treating or ameliorating metabolic disorders using combinations of GIPR binding proteins and GLP-1 agonists | 美国安进公司 | 2023-07-21 | — | — | CN | claimed |
| CN-116406360-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-07-07 | — | — | CN | claimed |
| US-6465463-B1 | PREVENTING MORTALITY IN AFRICAN AMERICAN PATIENTS HAVEING HYPERTENSION | NITROMED, INC. | 2002-10-15 | — | — | US | claimed |
| EP-1244455-A1 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | Nitromed, Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| EP-1212053-A1 | METHODS OF TREATING AND PREVENTING CONGESTIVE HEART FAILURE WITH HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE | Nitromed, Inc. (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2002034303-A1 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | NITROMED, INC. (US) | 2002-05-02 | — | — | WO | claimed |
| WO-2001035961-A1 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | NITROMED, INC. (US) | 2001-05-25 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2001017528-A1 | METHODS OF TREATING AND PREVENTING CONGESTIVE HEART FAILURE WITH HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE | NITROMED, INC. (US) | 2001-03-15 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |